This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alexander, H. R. Articles by Libutti, S. K. Search for Related Content PubMed PubMed Citation Articles by Alexander, H. R., Jr. Articles by Libutti, S. K.

Current Status of Isolated Hepatic Perfusion With or Without Tumor Necrosis Factor for the Treatment of Unresectable Cancers Confined to Liver

Surgical Metabolism Section, Surgery Branch, Division of Clinical Sciences, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA

Correspondence: H. Richard Alexander, Jr., M.D., Head, Surgical Metabolism Section, Surgery Branch, NCI, NIH, Building 10, Room 2B07, Bethesda, Maryland 20892, USA. Telephone: 301-496-2195; Fax: 301-402-1788.

ABSTRACT

Metastatic or primary unresectable cancers confined to the liver are the sole or life-limiting component of disease for many patients with colorectal cancer, ocular melanoma, neuroendocrine tumors or primary colangio- or hepatocellular carcinomas. A number of regional treatment strategies including infusional chemotherapy and local ablative therapy are under clinical development and attest to the difficulty in adequately treating this condition. Isolated hepatic perfusion (IHP) was first clinically applied over 40 years ago, but because of its technical complexity, the attendant potential morbidity, and the lack of documented efficacy, it has not gained widespread application. In light of the remarkable antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for unresectable liver cancers. IHP with TNF and melphalan can result in significant regression of advanced refractory cancers confined to the liver and, with additional clinical development, will most likely be a more routinely considered option for patients with this condition.

Key Words. Isolation perfusion • Tumor necrosis factor • Metastatic cancer of the liver • Melphalan • Unresectable cancers

This article has been cited by other articles:

				S. Onozawa, S. Murata, A. Shimizu, H. Tajima, F. Hidaka, S.-i. Kumita, and K. Nomura Comparative Study of Transcatheter Renal Arterial Embolization with and without Closed Renal Circuit: Pharmacokinetic and Histologic Assessment in Pigs Radiology, March 1, 2009; 250(3): 714 - 720. [Abstract] [Full Text] [PDF]

				B. Wielockx, J. Staelens, L. Puimege, I. Vanlaere, M. Van Roy, P. van Lint, F. Van Roy, and C. Libert Description and Mapping of the Resistance of DBA/2 Mice to TNF-Induced Lethal Shock J. Immunol., April 15, 2007; 178(8): 5069 - 5075. [Abstract] [Full Text] [PDF]

				M. Kresse, M. Latta, G. Kunstle, H.-M. Riehle, N. van Rooijen, H. Hentze, G. Tiegs, M. Biburger, R. Lucas, and A. Wendel Kupffer Cell-Expressed Membrane-Bound TNF Mediates Melphalan Hepatotoxicity via Activation of Both TNF Receptors J. Immunol., September 15, 2005; 175(6): 4076 - 4083. [Abstract] [Full Text] [PDF]

				J. F. Pingpank, S. K. Libutti, R. Chang, B. J. Wood, Z. Neeman, A. W. Kam, W. D. Figg, S. Zhai, T. Beresneva, G. D. Seidel, et al. Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies J. Clin. Oncol., May 20, 2005; 23(15): 3465 - 3474. [Abstract] [Full Text] [PDF]

				H. R. Alexander Jr., S. K. Libutti, J. F. Pingpank, S. M. Steinberg, D. L. Bartlett, C. Helsabeck, and T. Beresneva Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver Clin. Cancer Res., December 15, 2003; 9(17): 6343 - 6349. [Abstract] [Full Text] [PDF]